Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. Akebia Therapeutics, Inc. is not very popular among insiders. Akebia Therapeutics, Inc. is a mediocre stock to choose.
Log in to see more information.
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and comme...
AKBA Fundamental Data by TradingView

News

Akebia Therapeutics (NASDAQ:AKBA) Receives "Buy" Rating from HC Wainwright
Akebia Therapeutics (NASDAQ:AKBA) Receives "Buy" Rating from HC Wainwright

Zolmax Akebia Therapeutics (NASDAQ:AKBA - Get Free Report)s stock had its "buy" rating reissued by research analysts at HC Wainwright in a report issued on Friday, Benzinga reports. They currently...\n more…

When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?
When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?

Simply Wall St We feel now is a pretty good time to analyse Akebia Therapeutics, Inc.'s ( NASDAQ:AKBA ) business as it appears the...\n more…

Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo (vadadustat) for Patients on Dialysis
Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo (vadadustat) for Patients on Dialysis

PR Newswire Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo (vadadustat) for Patients on Dialysis Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo...\n more…

Short Interest in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Increases By 5.9%
Short Interest in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Increases By 5.9%

Ticker Report Akebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) saw a significant increase in short interest in the month of August. As of August 15th, there was short interest totalling 18,950,000 shares...\n more…

Short Interest in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Increases By 5.9%
Short Interest in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Increases By 5.9%

Zolmax Akebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) saw a large increase in short interest during the month of August. As of August 15th, there was short interest totalling 18,950,000 shares...\n more…

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass...\n more…